In vitro and in vivo analysis shows nintedanib inhibits tumor growth in triple-negative breast cancer, suggesting TP73 modulation may improve outcomes.
Key Points
Nintedanib significantly inhibited TNBC cell proliferation and induced apoptosis, showcasing its therapeutic potential against aggressive tumors.
Cell cycle analysis revealed nintedanib promotes arrest at the G2/M phase, emphasizing its effects on cell growth dynamics in TNBC.
Drafted in vitro and in vivo models demonstrated nintedanib's capability to disrupt the p53-PPARα/PI3K-Akt signaling axis effectively.
Study highlights the importance of targeting TP73 and EMT markers for enhanced therapeutic strategies in triple-negative breast cancer.